BR112019011961A2 - formulação tópica, método para prover tratamento não-sistêmico prolongado para dor em um indivíduo humano necessitando do mesmo, método para formar um depósito subcutâneo de detomidina ou um sal do mesmo em um indivíduo humano, formulação tópica e método para prover o tratamento para dor em um indivíduo humano necessitando do mesmo - Google Patents
formulação tópica, método para prover tratamento não-sistêmico prolongado para dor em um indivíduo humano necessitando do mesmo, método para formar um depósito subcutâneo de detomidina ou um sal do mesmo em um indivíduo humano, formulação tópica e método para prover o tratamento para dor em um indivíduo humano necessitando do mesmo Download PDFInfo
- Publication number
- BR112019011961A2 BR112019011961A2 BR112019011961-2A BR112019011961A BR112019011961A2 BR 112019011961 A2 BR112019011961 A2 BR 112019011961A2 BR 112019011961 A BR112019011961 A BR 112019011961A BR 112019011961 A2 BR112019011961 A2 BR 112019011961A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- detomidine
- salt
- formulation according
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443174P | 2017-01-06 | 2017-01-06 | |
| PCT/US2018/012579 WO2018129313A1 (en) | 2017-01-06 | 2018-01-05 | Topical detomidine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019011961A2 true BR112019011961A2 (pt) | 2019-11-05 |
Family
ID=61054537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019011961-2A BR112019011961A2 (pt) | 2017-01-06 | 2018-01-05 | formulação tópica, método para prover tratamento não-sistêmico prolongado para dor em um indivíduo humano necessitando do mesmo, método para formar um depósito subcutâneo de detomidina ou um sal do mesmo em um indivíduo humano, formulação tópica e método para prover o tratamento para dor em um indivíduo humano necessitando do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190343805A1 (enExample) |
| EP (1) | EP3565526B1 (enExample) |
| JP (1) | JP2020505322A (enExample) |
| KR (1) | KR20190110561A (enExample) |
| CN (1) | CN110114059A (enExample) |
| AU (1) | AU2018205217B2 (enExample) |
| BR (1) | BR112019011961A2 (enExample) |
| CA (1) | CA3049389A1 (enExample) |
| DK (1) | DK3565526T3 (enExample) |
| ES (1) | ES2982022T3 (enExample) |
| HU (1) | HUE068070T2 (enExample) |
| IL (1) | IL266448B2 (enExample) |
| MX (1) | MX382949B (enExample) |
| PL (1) | PL3565526T3 (enExample) |
| WO (1) | WO2018129313A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020012415A2 (en) * | 2018-07-11 | 2020-01-16 | Clexio Biosciences Ltd. | Topical detomidine formulations |
| WO2020016827A1 (en) * | 2018-07-18 | 2020-01-23 | Clexio Biosciences Ltd. | Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water |
| BR112021020962A2 (pt) | 2019-05-01 | 2021-12-14 | Clexio Biosciences Ltd | Métodos de tratamento de prurido |
| US20220211672A1 (en) | 2019-05-01 | 2022-07-07 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10256774A1 (de) * | 2002-12-05 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption |
| FI20041425A0 (fi) * | 2004-11-05 | 2004-11-05 | Orion Corp | Transmukosaalinen veterinäärinen koostumus |
| WO2011127586A1 (en) * | 2010-04-15 | 2011-10-20 | The Royal Institution For The Advancement Of Learning / Mcgill University | Topical treatments for pain |
| WO2013076160A1 (en) * | 2011-11-21 | 2013-05-30 | Université Libre de Bruxelles | Sustained release formulations useful in the treatment of diseases |
| EP2803668A1 (en) * | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| CA2921221A1 (en) * | 2013-08-14 | 2015-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
| US20150057351A1 (en) * | 2013-08-22 | 2015-02-26 | Sucampo Ag | Method for treating neuropathic pain |
-
2018
- 2018-01-05 CA CA3049389A patent/CA3049389A1/en active Pending
- 2018-01-05 BR BR112019011961-2A patent/BR112019011961A2/pt not_active IP Right Cessation
- 2018-01-05 CN CN201880005492.XA patent/CN110114059A/zh active Pending
- 2018-01-05 HU HUE18701853A patent/HUE068070T2/hu unknown
- 2018-01-05 PL PL18701853.6T patent/PL3565526T3/pl unknown
- 2018-01-05 ES ES18701853T patent/ES2982022T3/es active Active
- 2018-01-05 IL IL266448A patent/IL266448B2/en unknown
- 2018-01-05 AU AU2018205217A patent/AU2018205217B2/en active Active
- 2018-01-05 EP EP18701853.6A patent/EP3565526B1/en active Active
- 2018-01-05 DK DK18701853.6T patent/DK3565526T3/da active
- 2018-01-05 JP JP2019531615A patent/JP2020505322A/ja active Pending
- 2018-01-05 MX MX2019008115A patent/MX382949B/es unknown
- 2018-01-05 WO PCT/US2018/012579 patent/WO2018129313A1/en not_active Ceased
- 2018-01-05 KR KR1020197023046A patent/KR20190110561A/ko not_active Ceased
- 2018-01-05 US US16/475,452 patent/US20190343805A1/en not_active Abandoned
-
2023
- 2023-01-30 US US18/161,215 patent/US20230172909A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018129313A1 (en) | 2018-07-12 |
| IL266448A (en) | 2019-06-30 |
| MX382949B (es) | 2025-03-13 |
| ES2982022T3 (es) | 2024-10-14 |
| JP2020505322A (ja) | 2020-02-20 |
| AU2018205217B2 (en) | 2023-11-09 |
| US20230172909A1 (en) | 2023-06-08 |
| IL266448B1 (en) | 2023-07-01 |
| EP3565526B1 (en) | 2024-04-17 |
| MX2019008115A (es) | 2019-10-24 |
| CN110114059A (zh) | 2019-08-09 |
| US20190343805A1 (en) | 2019-11-14 |
| EP3565526A1 (en) | 2019-11-13 |
| CA3049389A1 (en) | 2018-07-12 |
| IL266448B2 (en) | 2023-11-01 |
| PL3565526T3 (pl) | 2024-09-09 |
| AU2018205217A1 (en) | 2019-05-23 |
| KR20190110561A (ko) | 2019-09-30 |
| DK3565526T3 (en) | 2024-05-13 |
| HUE068070T2 (hu) | 2024-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2445443T3 (es) | Solución tópica no acuosa de diclofenaco y proceso para la preparación de la misma | |
| US20230172909A1 (en) | Topical detomidine formulations | |
| US8609722B2 (en) | Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine | |
| PL207845B1 (pl) | Spray donosowy do dostarczania kompozycji farmaceutycznej zawierającej fentanyl i zastosowanie soli fentanylu do wytwarzania środka leczniczego | |
| BR112020003025A2 (pt) | métodos de tratamento de osteoartrite com gel transdérmico de canabidiol | |
| CA2761744A1 (en) | Methods for administration and formulations for the treatment of regional adipose tissue | |
| US11285099B2 (en) | Topical phenytoin for use in the treatment of peripheral neuropathic pain | |
| ES2585253T3 (es) | Composiciones para prevenir la pérdida de cabello o para estimular el crecimiento del cabello | |
| US10137079B2 (en) | Transdermal composition for treating pain | |
| US20050014823A1 (en) | Topical anesthetic composition and method of administration | |
| AU2012370410A1 (en) | Drug delivery technology | |
| CA2422531C (en) | Topical analgesic compositions containing aliphatic polyamines and methods of using same | |
| KR20080097420A (ko) | 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물 | |
| US20100190860A1 (en) | Methods for selectively enhancing antinociceptive potency of local anesthetics | |
| US20220313627A1 (en) | Onychomycosis Treatment Compositions and Methods | |
| TWI482633B (zh) | 用以延長局部麻醉劑止痛的方法與組合物 | |
| US20130338098A1 (en) | Topical Analgesic Compositions Containing Aliphatic Polyamines and Methods of Using Same | |
| Kang | Development of a Transdermal Microneedle Patch for Conscious Sedation in Pediatric Dentistry | |
| Ando et al. | Clinical evaluation of superficial anesthetic products to mitigate pain due to injection of local anesthetic into the gingival | |
| BR112021003746B1 (pt) | Formulação para distribuição transdérmica de um ingrediente ativo a um mamífero, e kit | |
| BR112021003746A2 (pt) | sistema de distribuição transdermal de fármacos | |
| Thacker et al. | EFFECT OF ADDING FENTANYL TO LOCAL ANAESTHETICS IN BRACHIAL PLEXUS BLOCK ON THE ONSET AND DURATION OF ANESTHESIA AND POSTOPERATIVE ANALGESIA | |
| JP2014019697A (ja) | 抗真菌外用組成物及び抗真菌外用組成物の適用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2808 DE 29-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |